Important Safety Information and Indications
LEVOXYL is indicated for hypothyroidism—as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism.
LEVOXYL is indicated for pituitary TSH suppression—in the treatment or prevention of various types of euthyroid goiters including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis) multinodular goiter and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Protecting Your Prescription
Substitution Is Possible at the Pharmacy
- Unless your prescription indicates no substitutions, the pharmacy may switch your patients to a generic equivalent. If this occurs, patients should have their TSH levels retested 8 to 12 weeks after taking the new medication1
You Can Help Protect Their Script
- If you prescribe brand-name LEVOXYL and want your patients to receive the brand at the pharmacy, always indicate no substitutions
- To ensure the brand you choose is dispensed as written, write or select one of the following, depending on the state you live in:
- Dispense As Written (DAW)
- Brand Medically Necessary
- No Substitutions
Download this Tip Sheet that provides helpful instructions on how to check for and receive brand-name LEVOXYL at the pharmacy, and give this to your patients.